DNA Repair Drug Development for Brain Tumors
DNA repair drugs bring new hope to the treatment of brain tumors by repairing damaged DNA to inhibit the growth and spread of tumor cells. Alfa Cytology offers development of DNA repair drugs for brain tumors, dedicated to pioneering innovative advancements to improve prognoses.
Introduction to DNA Damage Repair Pathway
DNA repair mechanisms play a critical role in maintaining genomic stability and preventing the accumulation of mutations within cells. In the development of brain tumors, these repair pathways are often altered or impaired, leading to the accumulation of DNA damage that promotes tumor initiation and progression. A deeper understanding of the changes in DNA repair mechanisms specific to brain tumors not only helps to elucidate the pathogenic mechanisms underlying tumorigenesis but also provides new avenues for developing targeted therapies that focus on specific repair pathways.
Fig 1. DNA damage repair pathway. (ZHAO S, et al., 2021)
Types of DNA Repair Mechanism
Direct Repair
The MGMT enzyme directly reverses alkylation damage, such as O⁶-methylguanine, without the need to excise the DNA strand.
Mismatch Repair (MMR)
MMR corrects DNA replication errors, such as base mismatches. The MutSα/MutLα complexes recognize these errors and excise the error-containing DNA strand.
Base Excision Repair (BER)
This pathway targets small base lesions like oxidation or deamination. Glycosylases recognize and remove the abnormal bases, creating an abasic (AP) site. Subsequently, AP endonuclease, DNA polymerase β, and ligase III collaborate to complete the repair.
Nucleotide Excision Repair (NER)
NER repairs large-scale helix-distorting damages, such as pyrimidine dimers. It is divided into global genome repair and transcription-coupled repair. Damage is recognized by the XPC protein, and after helicases unwind the DNA, a 24-32 nucleotide-long fragment containing the lesion is excised.
Our Services
Drugs that exert anti-brain tumor effects by modulating epigenetic genes are becoming a hot topic of research. Alfa Cytology provides epigenetically targeted drug development services for clients in the field of brain tumor research. Given a large number of potential targets, we have developed a systematic approach to discover and validate potential drug targets to focus on helping our clients in brain tumor drug development and improving drug efficacy.
| Therapeutic Targets in DNA Repair Pathway for Brain Tumors |
| DNMT1 |
DNMT13A |
DNMT13B |
EZH2 |
DOT1L |
KMT2A-D |
| SETD2 |
NSDI |
EP300 |
CREBBP |
TET2 |
IDH1 |
| IDH2 |
HDAC1 |
HDAC2 |
HDAC3 |
HDAC6 |
HDAC8 |
| KDMIA |
KDM6A (UTX) |
BRD4 |
CBX family |
CHD1 |
ARIDIA |
| ARID1B |
ARID2 |
SMARCA2 |
SMARCA4 |
SMARCBI |
HIST1H1B |
| HIST1HIC |
HISTIH3B |
H3F3A |
H3F3B |
CTCF |
STAG2 |
| RAD21 |
CHD8 |
|
|
|
|
DNA Repair Drug Development for Brain Tumors
Alfa Cytology researches various types of DNA repair drugs for the treatment of brain tumors. By targeting the DNA repair mechanisms within cancer cells, we aim to develop innovative therapies that enhance treatment effectiveness and overcome drug resistance.
Radionuclide Therapy
Immune Cell Therapy
Evaluation for DNA Repair Drugs
Alfa Cytology performs cell-based assays to evaluate the efficacy of DNA repair inhibitors on brain tumor cells.
- High-Throughput Screening
- DNA Damage and Repair Assays
- Cytotoxicity and Cell Viability Tests
- Apoptosis Analysis
- Cell Cycle Analysis
- Gene Expression Profiling
We conduct animal studies to assess the therapeutic potential of DNA repair drug candidates in brain tumor models.
- Animal Model Development
- Pharmacokinetic Studies
- Biodistribution Analysis
- Blood-Brain Barrier Penetration Studies
- Tumor Growth Inhibition Studies
- Survival Analysis
- Safety and Toxicity Assessments
Disorders of chromatin epigenetic modifications are seen in the pathology of many major diseases such as brain tumors, and cardiovascular and cerebrovascular. Therefore, there is an urgent need for drugs that can intervene in epigenetic modification disorders in disease states. In response to this need, Alfa Cytology offers its clients epigenetically targeted drug development services for brain tumors. You can
contact us at any time to receive updates on our services.
Reference
- ZHAO S, XU B, MA W, et al. DNA Damage Repair in Brain Tumor Immunotherapy [J]. Frontiers in immunology, 2021, 12: 829268.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
